



**Faculty disclosures report - As of November 7, 2022**

The MPNCO&D 2022 Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of MPNCO&D 2022 participants. In doing so, the MPNCO&D 2022 Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

**Educational Content Development**

The MPNCO&D 2022 Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

**Presenters**

The MPNCO&D 2022 Congress considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the MPNCO&D 2022 Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the MPNCO&D 2022 Congress of CME based on the CME providers of the Congress.

All MPNCO&D 2022 Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The MPNCO&D 2022 Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

**MPNCO&D 2022 Financial Disclosure Codes**

Type of affiliation / financial interest	Code
Receipt of grants/research supports:	S
Receipt of consultation / advisory board / employment fees:	C
Lecture and/or honoraria fees:	L
Stock shareholder or equity owner:	O
Patents/royalties:	P
Nothing to declare: <i>Written as said statement</i>	
Other: <i>Written as stated on submitted form</i>	

**Disclosure Information**

Financial interest disclosures from program members and others in a position for control content:



1<sup>st</sup> Congress on Myeloproliferative Neoplasms Controversies and Debates  
(MPNCo&D), November 11-12, 2022 – Virtual Event

<https://mpnlive.cme-congresses.com/>

**Prithviraj Bose, USA**

- S Incyte, BMS, CTI, Kartos, Constellation (MorphoSys), Blueprint, Cogent, Ionis, Disc Medicine, Astellas, Pfizer, NS Pharma, Promedior
- C Incyte, BMS, CTI, Kartos, Constellation (MorphoSys), Blueprint, Cogent, Novartis, Sierra Oncology (GSK), AbbVie, PharmaEssentia, Karyopharm

**Angela Fleischman, USA**

*Nothing to declare*

**Aaron Gerds, USA**

- C CTI Biopharma, MorphoSys, AbbVie, Imago, Sierra Oncology, PharmaEssentia

**Jason Gotlib, USA**

*Nothing to declare*

**Claire Harrison, UK**

*Nothing to declare*

**Ian Hitchcock, UK**

- S Incyte, AstraZeneca

**Gabriela Hobbs, USA**

- S ASH-AMFDP, Incyte
- C AbbVie, Blueprint, Pharmaxis, Incyte, Pfizer, Novartis

**Ronald Hoffman, USA**

- S Novartis, Turning Rock, AbbVie, OncomyX, CTI

**Tania Jain, USA**

- S Incyte, Syneos Health, CTI Biopharma

**Joseph Khoury, USA**

*Nothing to declare*

**Jean-Jacques Kiladjian, France**

- C Novartis, AbbVie, Incyte, BMS, AOP Orphan

**Steffen Koschmieder, Germany**

- S Geron, Janssen, AOP Pharma, Novartis
- C,L Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI Biopharma, Roche, Bayer, PharmaEssentia

**Nicole Kucine, USA**

- Other Member of SMB – Protagonist Therapeutics, LLC

**Andrew Kuykendall, USA**

- S Sierra Oncology, Prelude, Protagonist, Celgene/BMS, Blueprint, MorphoSys
- C AbbVie, Protagonist
- L Blueprint





1<sup>st</sup> Congress on Myeloproliferative Neoplasms Controversies and Debates  
(MPNCo&D), November 11-12, 2022 – Virtual Event

<https://mpnlive.cme-congresses.com/>

**Sanam Loghavi, USA**

Other Co-author on the new WHO classification for hematopoietic neoplasms which will be discussed within presentation at MPNCo&D

**Lucia Masarova, USA**

*Nothing to declare*

**John Mascarenhas, USA**

S Incyte, Novartis, Geron, Merck, CTI Biopharma, BMS, Celgene, AbbVie, Kartos, PharmaEssentia  
C CTI, Incyte, Novartis, Roche, GSK, AbbVie, Geron, Karyopharm, BMS, Celgene, Kartos, PharmaEssentia, Galecto, Constellation

**Ruben Mesa, USA**

*Nothing to declare*

**Laura Michaelis, USA**

S Jazz Pharmaceuticals  
C AbbVie, Curio Science, Celgene, Incyte

**Kamran Mirza, USA**

L Astellas

**Ann Mullally, USA**

S Relay Therapeutics  
C Aclaris Therapeutics, Cellarity, Morphic Therapeutics, Biomarin Pharmaceuticals  
L PharmaEssentia

**Jyoti Nangalia, UK**

*Nothing to declare*

**Stephen Oh, USA**

C AbbVie, Constellation, CIT Biopharma, BMS, Geron, Sierra Oncology, Cogent, Incyte

**Mrinal Patnaik, USA**

C Kura Oncology, Stemline Pharmaceuticals

**Naveen Pemmaraju, USA**

S US Department of Defense, SagerStrong Foundation, Affymetrix  
C AbbVie, Aptitude Health, Astellas, Blueprint Medicines, BMS, Celgene, Cimeio Therapeutics, ClearView Healthcare Partners, CTI Biopharma, Dava Oncology, Immunogen, Incyte, Intellisphere, Novartis AG, Novartis Pharmaceuticals Corp, Onclive, Patient Power, PharmaEssentia, Protagonist Therapeutics, Sanofi-Aventis, Total CME, Cancer.Net, CareDx, FUSA Pharma, Pacylex  
L AbbVie, Aplastic Anemia & MDS International Foundation, Curio Science, Dava Oncology, Imedex, Magdalen Medical Publishing, Medscape, Neopharm, PeerView Institute for Medical Education, PER, Stemline  
O Karger Publishes

**Deepti Radia, UK**

S Blueprint Medicines  
C Blueprint Medicines, Cogent Biosciences, Novartis  
L Blueprint Medicines, Novartis





1<sup>st</sup> Congress on Myeloproliferative Neoplasms Controversies and Debates  
(MPNCo&D), November 11-12, 2022 – Virtual Event

<https://mpnlive.cme-congresses.com/>

**Raajit Rampal, USA**

*Nothing to declare*

**Andreas Reiter, Germany**

S,C Novartis, Blueprint Medicines, Incyte, BMS, AbbVie, AOP, GSK

**Susan Robinson, UK**

C Novartis

**Daniel Royston, UK**

S Roche Ltd

C Perspectum Ltd

**Richard Silver, USA**

*Nothing to declare*

**Jerry Spivak, USA**

*Nothing to declare*

**David Steensma, USA**

Other Novartis employee

**Brady Stein, USA**

C PharmaEssentia

**Alessandro Vannucchi, Italy**

C,L Novartis, Incyte, GSK, BMS, Blueprint, AbbVie

**Srdan Verstovsek, USA**

S Incyte, Novartis, Sierra, Blueprint, Celgene, BMS, CTI, Protagonist, PharmaEssentia

C Novartis, Incyte, Sierra, BMS

**Daniel Wiseman, UK**

S Astex Pharmaceuticals

C Novartis, Gilead, Jazz Pharmaceuticals, Blueprint, Stemline

**Ibrahim Yakoub-Agha, France**

C Novartis